Homo sapiens strain:MCF7 Tamoxifen resistant cancer cell line Raw sequence reads

Although 70% of estrogen receptor (ER)-positive breast cancer patients can benefit from Tamoxifen therapy, the developing resistance to Tamoxifen remains result in high rates of metastasis and poor prognosis in breast cancer. Propofol is a commonly used anesthetic that can significantly inhibit the occurrence and development of breast cancer. However, its role in anti-endocrine resistance of ER- positive breast cancer has not been elucidated. In this study, we found that Propofol could significantly promote cell cycle arrest, induce the apoptosis, and inhibit the proliferation in Tamoxifen-resistant breast cancer cells. Furthermore, we used trancriptome sequencing to analysis the gene expression profiles in human breast adenocarcinoma cell line (MCF7) resistant to Tamoxifen (MCF7-TR) after treatment with Propofol. The results of RNA-seq showed that a total of 1065 differentially expressed genes (DEGs) between Propofol-treated MCF7-TR cells and control cells. Gene ontology annotation enrichment analysis (GO), Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis (KEGG) and The gene set enrichment analysis (GSEA) showed that Propofol affected the expression of genes located in plasma membrane and cell periphery, mainly regulating the signals involving in cell cycle, immune response and metabolism. Our results revealed a new insight of the mechanism by which Propofol controls the progression of resistance to Tamoxifen in breast cancer, and provided a theoretical basis for clinical medication of breast cancer.